Vanguard Group Inc. Grows Stock Holdings in Harrow Health, Inc. (NASDAQ:HROW)

Vanguard Group Inc. increased its stake in Harrow Health, Inc. (NASDAQ:HROW - Free Report) by 5.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,759,879 shares of the company's stock after buying an additional 95,389 shares during the period. Vanguard Group Inc. owned 5.01% of Harrow Health worth $25,289,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Westside Investment Management Inc. raised its stake in Harrow Health by 18.9% in the third quarter. Westside Investment Management Inc. now owns 159,019 shares of the company's stock worth $2,285,000 after buying an additional 25,275 shares in the last quarter. Morgan Stanley raised its stake in Harrow Health by 0.5% in the third quarter. Morgan Stanley now owns 1,777,661 shares of the company's stock worth $25,545,000 after buying an additional 8,364 shares in the last quarter. Kennedy Capital Management LLC bought a new position in Harrow Health in the third quarter worth about $1,750,000. Stansberry Asset Management LLC raised its stake in Harrow Health by 9.7% in the third quarter. Stansberry Asset Management LLC now owns 139,423 shares of the company's stock worth $2,004,000 after buying an additional 12,293 shares in the last quarter. Finally, Braidwell LP raised its stake in Harrow Health by 24.5% in the third quarter. Braidwell LP now owns 1,808,684 shares of the company's stock worth $25,991,000 after buying an additional 356,146 shares in the last quarter. 72.76% of the stock is owned by institutional investors.

Insider Activity

In other news, major shareholder Opaleye Management Inc. purchased 50,600 shares of the business's stock in a transaction dated Wednesday, March 20th. The shares were purchased at an average price of $9.65 per share, for a total transaction of $488,290.00. Following the completion of the acquisition, the insider now directly owns 3,695,600 shares in the company, valued at approximately $35,662,540. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Mark L. Baum bought 9,000 shares of the company's stock in a transaction that occurred on Friday, March 22nd. The shares were bought at an average price of $11.59 per share, for a total transaction of $104,310.00. Following the completion of the acquisition, the chief executive officer now owns 2,137,525 shares of the company's stock, valued at approximately $24,773,914.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Opaleye Management Inc. bought 50,600 shares of the company's stock in a transaction that occurred on Wednesday, March 20th. The stock was bought at an average price of $9.65 per share, for a total transaction of $488,290.00. Following the acquisition, the insider now directly owns 3,695,600 shares of the company's stock, valued at approximately $35,662,540. The disclosure for this purchase can be found here. Insiders have bought a total of 109,600 shares of company stock worth $1,233,600 over the last 90 days. 13.60% of the stock is currently owned by insiders.

Harrow Health Stock Down 4.1 %

Shares of NASDAQ HROW traded down $0.54 on Friday, reaching $12.65. 347,933 shares of the company's stock traded hands, compared to its average volume of 618,999. Harrow Health, Inc. has a 12 month low of $7.60 and a 12 month high of $28.25. The business's 50 day simple moving average is $11.47 and its two-hundred day simple moving average is $11.43. The company has a market cap of $447.30 million, a price-to-earnings ratio of -16.87 and a beta of 0.48. The company has a quick ratio of 2.61, a current ratio of 2.83 and a debt-to-equity ratio of 2.60.

Harrow Health (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Tuesday, March 19th. The company reported ($0.27) EPS for the quarter. Harrow Health had a negative net margin of 18.75% and a negative return on equity of 29.48%. The firm had revenue of $36.36 million for the quarter, compared to analysts' expectations of $37.65 million. As a group, equities research analysts forecast that Harrow Health, Inc. will post -0.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. B. Riley decreased their target price on shares of Harrow Health from $30.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, March 22nd. Craig Hallum assumed coverage on shares of Harrow Health in a research note on Thursday. They set a "buy" rating and a $24.00 target price for the company.

About Harrow Health

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.